Advanced Life Sciences Holdings Inc.

Michael T. Flavin, Ph.D., Chief Executive Officer and Chairman, founded Advanced Life Sciences, Inc. in 1999. Prior to this date, he was the founder, Chief Executive Officer and Chairman of MediChem Life Sciences, Inc., a drug discovery technology and services company. Dr. Flavin took MediChem from start-up in 1987 through many stages of development including the completion of MediChem's private placement, the acquisition and integration of ThermoGen and Emerald Biostructures as MediChem subsidiaries and MediChem's initial public offering in October 2000. MediChem was acquired in March 2002 by deCODE genetics. Dr. Flavin was the Chief Executive Officer of MediChem, as a subsidiary of deCODE, through May 2002. Dr. Flavin received a B.S. in Chemistry from the University of Notre Dame, a Ph.D. in Medicinal Chemistry from the University of Illinois at Chicago and he completed a postdoctoral fellowship at Harvard University. Dr. Flavin is an Adjunct Professor for the Department of Medicinal Chemistry & Pharmacognosy at the University of Illinois at Chicago.

Gordon R. Bernard, M.D., is Chief of Pulmonary Service and Professor of Medicine at Vanderbilt University School of Medicine. In addition, he is Medical Director for the Institutional Review Board. Dr. Bernard is a leader in the area of cardiopulmonary medicine and sepsis research and he has published more than 100 peer-reviewed articles on these topics. He chairs the Steering Committee for NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Dr. Bernard received his M.D. degree from Louisiana State University. He serves on the editorial boards of Clinical Intensive Care, Journal of Critical Care and Sepsis.

Michael J. Cogan, Vice President and Controller, joined us in October 2004 as our Director of Finance and Controller. From 2003 to 2004 Mr. Cogan served as the Corporate Controller for the PRIMIS Marketing Group, a venture backed direct marketing firm located in Chicago, IL. From 1996 to 2003 Mr. Cogan served as the Corporate Controller for MediChem Life Sciences where he directed the accounting and finance functions through several rounds of private financing, an initial public offering and multiple acquisition transactions. Mr. Cogan earned his C.P.A. after graduating from the University of Illinois with a B.S. in accounting and a B.S. in Finance. He also holds an M.B.A. from DePaul University.

Patrick W. Flavin, J.D., Chief Legal Counsel, joined us in November 2002 as legal counsel. He was promoted to Chief Legal Counsel in 2004. Prior to joining us, Mr. Flavin served as a counsel to the Illinois Speaker of the House from January 2002 to November 2002. Prior to this position, he was the Director of Legal Affairs for MediChem Life Sciences from May 2000 to September 2001, where he managed the in-house legal staff and outside legal counsel. Mr. Flavin obtained his B.A. from Providence College and received his J.D. from DePaul University College of Law. Mr. Flavin is the brother of Michael T. Flavin, Ph.D. and John L. Flavin.

Ze-Qi Xu, Ph.D., Chief Scientific Officer, joined us in October 2002 from MediChem Life Sciences, Inc. From January 2000 until September 2002, Dr. Xu was the Vice President of Strategic Drug Development at MediChem and oversaw the discovery, preclinical and clinical development of Calanolide A as well as the preclinical development of ALS-886 and ALS-357. Dr. Xu has published 52 articles and holds 19 patents in the fields of infectious disease and cancer. Dr. Xu earned a B.S. degree in Chemistry from Jiangxi Normal University (China), a M.S. degree in Organic Chemistry from Shanghai Medical University and a Ph.D. in Organic Chemistry from the Shanghai Institute of Organic Chemistry. He performed his postdoctoral fellowships at Clemson University and the Michigan Cancer Foundation.

David A. Eiznhamer, Ph.D., Executive Vice President of Clinical Development, joined us as Director of Biological Sciences in 2003 from MediChem Life Sciences, Inc., where he was the Assistant Director of Pharmacology and ADME from January 2002 to May 2003. Dr. Eiznhamer was promoted to Vice President of Biological Sciences in May 2004. In his role at MediChem, Dr. Eiznhamer was responsible for the design and development of pharmacology and ADME research programs. Prior to that, he served as the Manager of Regulatory Affairs for MediChem Life Sciences from December 1999 to January 2002. Dr. Eiznhamer also worked as a clinical coordinator for the Division of Gastroenterology at Loyola University Medical Center in Maywood, Illinois. He has authored seven publications and made 19 presentations at national and international meetings. Dr. Eiznhamer received his Ph.D. in Molecular Biology from Loyola University of Chicago.

Suseelan Pookote, Ph.D., Executive Vice President of Corporate Development, joined us in March 2001. Prior to joining us, Dr. Pookote worked at Monsanto from 1980 to 2000, where he had responsibility for technology and business development in a variety of industry segments such as food, nutrition, biotechnology and specialty chemicals. At Monsanto, Dr. Pookote concentrated on technology evaluation, licensing and corporate transactions, including the negotiation of technology licensing deals with academic institutions. Dr. Pookote received his Ph.D. in Chemical Engineering from Northwestern University.

Nicholas Volgelzang was appointed director of Nevada Cancer Institute (NVCI) in January of 2004. In January 2008, he was appointed executive vice president for Academic Affairs. As Director, Dr. Vogelzang is responsible for setting the direction for NVCI's research programs in clinical, basic and population science. In addition, he recruits the medical researchers and leaders for NVCI. He has authored more than 275 peer-reviewed papers, 16 internet publications, 71 reviews, 62 book chapters, 10 books/journal issues and 381 abstracts & letters. Prior to joining NVCI, Dr. Vogelzang served as the director of the University of Chicago Cancer Research Center. Dr. Vogelzang has served on numerous committees of the American Society of Clinical Oncology, as well as on its board of directors from 1993 to 1996. He is a former president of the Illinois Division of the American Cancer Society. Dr. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, chair of the CALGB Prostate Committee from 1993 to 1999 and principal investigator of the University of Chicago Cancer Center Support Grant. He is a member of many societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, the American Urological Association, the Kidney Cancer Association, the Society of Urologic Oncology and the European Society for Medical Oncology. In August 2006, he was elected chair of the board of directors of the Mesothelioma Applied Research Foundation (MARF). Dr. Vogelzang has served on the Editorial Boards of Cancer, Cancer Research, Clinical Genitourinary Cancer, The Prostate Journal, Seminars in Oncology and the Journal of Clinical Oncology, and is a reviewer for numerous other journals. He is the author of nearly 435 scientific publications (including peer-reviewed papers, internet publications, reviews, book chapters and books and journal issues), over 381 abstracts and letters, and has given over 350 scientific lectures. As a survivor of Hodgkin's disease, he is a sought-after public speaker. He is the lead editor of the Comprehensive Textbook of Genitourinary Oncology, third edition, which was published in 2005. Dr. Vogelzang is a recognized expert in new therapies for patients with metastatic kidney cancer, including genetic therapy. Dr. Vogelzang received his M.D. degree from the University of Illinois at Chicago in 1974. He completed his internship, residency and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. He served as a faculty member at the University of Chicago from 1982 - 2003 and is currently a professor of medicine at the University of Nevada School of Medicine.

Array

Israel Rubinstein, M.D., Director, joined our board of directors in May 2001. Dr. Rubinstein is Professor of Medicine and Biopharmaceutical Sciences in the Colleges of Medicine and Pharmacy at the University of Illinois at Chicago, where he has worked since 1993. Dr. Rubinstein is a leading physician and research scientist in respiratory medicine and oncology. He has served on the Editorial Boards of several medical journals and is grant reviewer for the NIH. Dr. Rubinstein received an M.D. degree from Hebrew University-Hadassah School of Medicine and completed fellowships in Respirology at the University of Toronto and in Cardiovascular Research at the University of California San Francisco.

Dr. Rosalie Sagraves is a professor of pharmacy practice at the University of Illinois at Chicago College of Pharmacy, a position she has held since 1995 and where she served as dean of the College from 1995 to 2006. Her areas of educational/research interest include pediatric critical care and pharmacotherapeutics, maternal-child health, and women’s health. She has authored more than 90 journal articles and book chapters. She is a speaker on pediatric pharmacotherapy and women’s health. She has served as Council of Deans chair for the American Association of Colleges of Pharmacy (AACP) and as a member of AACP board of directors, and as a member of the American Pharmacists Association (APhA, formerly the American Pharmaceutical Association) board of trustees. She has served as president of the APhA Academy of Pharmaceutical Research and Science and as associate editor and member of the editorial board of Pharmacy Today. She served as a column editor for the Journal of Pediatric Health Care. She is a fellow of APhA and of the American College of Clinical Pharmacy. She has had ongoing involvement with the Sister to Sister Foundation and its various national campaigns to advance women’s heart health. She served as a member of the National Institutes of Health Office of Research on Women’s Health (ORWH) advisory board and its Women’s Health Task Force, Research for the 21st Century. She continues to serve ORWH as a member of its Specialized Centers of Research External Advisory Committee. She has received awards for outstanding teaching and leadership. She attended Miami University and later graduated from The Ohio State University and the Philadelphia College of Pharmacy and Science (University of the Sciences in Philadelphia).

Thomas V. Thornton, Director, joined our board of directors in June 2001. Mr. Thornton is a successful early-stage venture capital investor and recognized leader in the development of public/ private technology development initiatives. From July 2001 to March 2002, Mr. Thornton was the Senior Vice President-Midwest Region for Convergent Technology Group, a mergers and acquisitions advisory services firm. From October 1999 to May 2001, Mr. Thornton was the Managing Partner for divine interVentures, Inc., a service and software company, and led seed- and early-stage venture investing teams that managed over $120 million and contributed to divine interVenture's initial public offering. Presently, Mr. Thornton is the president of the Illinois Technology Development Alliance, a public/private partnership established to strengthen Illinois' economy through science and technology. Mr. Thornton received a B.A. degree from the University of Wisconsin-Madison.